Literature DB >> 15246374

New chelation strategy allows for quick and clean 99mTc-labeling of synthetic peptides.

Dik Blok1, Hans I J Feitsma, Yvonne M C Kooy, Mick M Welling, Ferry Ossendorp, Pieter Vermeij, Jan W Drijfhout.   

Abstract

Analogues of bombesin have been synthesized in which a N2S2 (bis-mercaptoacetyl functionalized diaminopropionic acid) or a N3S (mercaptoacetyl-Gly-Gly-Gly) radiometal-chelating center has been incorporated that allows radiolabeling of these peptides with 99mTc without the need for conjugation or harsh reaction conditions. A mild radiolabeling is possible by using an acetyl-moiety as sulfur protecting group, which can be removed by mild hydroxylamine-treatment at room temperature before radiolabeling. Retained receptor binding is demonstrated in competitive binding experiments with 99mTc-radiolabeled peptides and PC-3 cells with bombesin receptors. Copyright 2004 Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15246374     DOI: 10.1016/j.nucmedbio.2004.02.009

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  4 in total

Review 1.  Radiolabeled bombesin derivatives for preclinical oncological imaging.

Authors:  Carolina de Aguiar Ferreira; Leonardo Lima Fuscaldi; Danyelle M Townsend; Domenico Rubello; André Luís Branco de Barros
Journal:  Biomed Pharmacother       Date:  2016-12-29       Impact factor: 6.529

2.  Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.

Authors:  Torun Engfeldt; Anna Orlova; Thuy Tran; Alexander Bruskin; Charles Widström; Amelie Eriksson Karlström; Vladimir Tolmachev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-05       Impact factor: 9.236

Review 3.  Targeting prostate cancer with radiolabelled bombesins.

Authors:  Theodosia Maina; Berthold Nock; Stephen Mather
Journal:  Cancer Imaging       Date:  2006-11-08       Impact factor: 3.909

4.  Preclinical Evaluation of 99mTc-Labeled GRPR Antagonists maSSS/SES-PEG2-RM26 for Imaging of Prostate Cancer.

Authors:  Ayman Abouzayed; Sara S Rinne; Hamideh Sabahnoo; Jens Sörensen; Vladimir Chernov; Vladimir Tolmachev; Anna Orlova
Journal:  Pharmaceutics       Date:  2021-01-30       Impact factor: 6.321

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.